Table 2 Different NS1-based vaccine strategies in mouse models

Protein

Full length NS1 + CFA adjuvant

Lethal amount of DENV2 (NGC) from suckling mouse brain/i.c.

CD1

88% survival; 35% reduction in morbidity

[98]

Recombinant vaccinia virusexpressed NS1

100 IC50 of DENV4 (H241) or DENV2 (NGC)/i.c.

BALB/c

63-100% survival

[116]

rEC204-NS1N65 –protein A

100 LD50 of DENV2 (NGC)/i.c.

BALB/c

100% survival

[117]

rNS1+ LTG33D adjuvant

4.32 log10 PFU of DENV2 (NGC)/i.c.

BALB/c

50% survival; 10% reduction in morbidity

[118]

ΔC NS1# + CFA adjuvant

9×107 PFU of DENV2 (16681)/i.d.

C3H/HeN

66% reduction in hemorrhage; rescue partial bleeding prolong

[96]

Chimeric DJ NS1## + CFA adjuvant

9×107 PFU of DENV2 (16681)/i.d.

C3H/HeN

66% reduction in hemorrhage; rescue partial bleeding prolong

[96]

Full DENV 1-4 NS1 + MPLA/AddaVax adjuvant

1×107 of DENV2 (adapted strain D220)/i.v.

Ifnar−/−C57BL/6

60-100% survival; reduce viremia and NS1 antigenemia

[38]

Subunit peptide

Modified NS1-WD^a+ CFA adjuvant

2×108 PFU of DENV1-4/i.d.; 4×107 PFU of DENV2 (454009A)/i.v.

C3H/HeN; STAT1-/- C57BL/6

100% survival; reduce viremia and NS1 antigenemia; 70-90% reduction in hemorrhage; rescue partial bleeding prolong

[97]

pD2NS1/pD2NS1+ pIL-2

5×106 -107 PFU of DENV2 (PL046)/i.v.

C3H

50-80% survival; 70-80% reduction in morbidity

[119]

DNA vaccine

pcTPANS1^b

4.32 log10 PFU of DENV2 (NGC)/i.c.

BALB/C

100% survival

[120, 121]

pcENS1^c

4.32 log10 PFU of DENV2 (NGC)/i.c.

BALB/C

86.7% survival; 60% reduction in morbidity

[122]